Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 21, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Engineered adenovirus serotypes for overcoming anti-vector immunity.

Sridhar Dharmapuri1, Daniela Peruzzi, Luigi Aurisicchio

  • 1IRBM P Angeletti, Via Pontina km 30.6, Pomezia 00040, Italy.

Expert Opinion on Biological Therapy
|August 4, 2009
PubMed
Summary

Adenovirus (Ad) vectors are promising for gene therapy and vaccines, but pre-existing immunity and inflammatory responses hinder their use. This review explores Ad biology and strategies to overcome these immune obstacles for improved applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic.

Journal for immunotherapy of cancer·2026
Same author

Novel Humanized Anti-HER3 Antibodies: Structural Characterization and Therapeutic Activity.

Antibodies (Basel, Switzerland)·2025
Same author

A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas.

Animals : an open access journal from MDPI·2024
Same author

Isolation and Characterization of Neutralizing Monoclonal Antibodies from a Large Panel of Murine Antibodies against RBD of the SARS-CoV-2 Spike Protein.

Antibodies (Basel, Switzerland)·2024
Same author

Relevance of Spike/Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2.

Signal transduction and targeted therapy·2023
Same author

Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms.

Vaccines·2023

Area of Science:

  • Biotechnology and Biomedical Engineering
  • Immunology
  • Gene Therapy

Background:

  • Adenovirus (Ad)-based vectors are widely used in gene therapy and vaccine development, with numerous clinical trials underway.
  • Recombinant Ad vectors show promise in applications for HIV, cancer immunotherapy, and other infectious diseases.
  • Innate and pre-existing immunity against Ad vectors presents a significant challenge to their effective development and application.

Purpose of the Study:

  • To review the biological mechanisms underlying adenovirus infection and vector-mediated immune responses.
  • To identify and discuss current strategies aimed at overcoming immunity against Ad-based gene transfer vectors.
  • To highlight the importance of addressing vector-mediated immunity for advancing Ad-based gene therapy and vaccine technologies.

More Related Videos

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Related Experiment Videos

Last Updated: Jun 21, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Main Methods:

  • Literature review focusing on the biology of adenovirus infection.
  • Analysis of research on pre-existing and innate immunity to adenovirus vectors.
  • Examination of various approaches developed to mitigate anti-adenovirus immune responses in gene therapy and vaccination.

Main Results:

  • Pre-existing immunity and inflammatory cytokine production significantly limit the efficacy and safety of Ad-based gene transfer.
  • These immune responses can reduce the duration of gene expression and cause adverse side effects.
  • Various strategies are being explored to circumvent or suppress these detrimental immune reactions.

Conclusions:

  • Overcoming vector-mediated immunity is crucial for the successful clinical application of adenovirus-based gene therapy and vaccines.
  • Continued research into Ad biology and immunomodulation is essential for optimizing Ad vector technology.
  • Addressing immune responses will enhance gene expression duration and improve the safety profile of Ad-based therapeutics.